SCHEMBL2064903

SCHEMBL2064903

Cc1ccc(-c2cn3cc(-c4ccc(F)c(CO)c4F)ccc3n2)cc1Cl

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 7/20 0.75
KCNH2 Q12809 2/20 0.43
CYP2C9 P11712 1/20 0.43
ALDH1A1 P00352 6/20 0.41
NPC1 O15118 5/20 0.41
RAB9A P51151 5/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
KDM4E B2RXH2 3/20 0.41
LMNA P02545 2/20 0.41
MAPT P10636 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
ALDH1A3 P47895 3/20 0.40
POLB P06746 1/20 0.39
PKM P14618 1/20 0.39
CASP6 P55212 1/20 0.39
GFER P55789 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2063623 0.92 NR4A2 (0.75) NR4A2KCNH2CYP2C9ALDH1A1NPC1
SCHEMBL2062962 0.88 NR4A2 (0.79) NR4A2KCNH2CYP2C9ALDH1A1NPC1
SCHEMBL2064621 0.88 NR4A2 (0.57) NR4A2KCNH2CYP2C9ALDH1A1NPC1
SCHEMBL2064008 0.86 NR4A2 (1.00) NR4A2KCNH2CYP2C9ALDH1A1NPC1
SCHEMBL3430036 0.84 NR4A2 (0.79) NR4A2KCNH2CYP2C9ALDH1A1NPC1
SCHEMBL2064134 0.82 NR4A2 (0.84) NR4A2KCNH2CYP2C9ALDH1A1NPC1
SCHEMBL2062937 0.82 NR4A2 (0.83) NR4A2KCNH2CYP2C9ALDH1A1NPC1
SCHEMBL2063547 0.81 NR4A2 (0.71) NR4A2KCNH2CYP2C9ALDH1A1NPC1
SCHEMBL6527461 0.80 NR4A2 (0.70) NR4A2KCNH2CYP2C9ALDH1A1NPC1
SCHEMBL3431357 0.80 NR4A2 (0.67) NR4A2KCNH2CYP2C9ALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2262803-B1 POLYSUBSTITUTED DERIVATIVES OF 2-ARYL-6-PHENYL-IMIDAZO[L,2-A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2012-10-17 EP claimed
US-8148370-B2 Polysubstituted derivatives of 2-aryl-6-phenyl-imidazo[1,2-a]pyridines, and preparation and therapeutic use thereof SANOFI-AVENTIS (FR) 2012-04-03 US claimed
US-20110065699-A1 POLYSUBSTITUTED DERIVATIVES OF 2-ARYL-6-PHENYL-IMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-03-17 US claimed
EP-2262803-B1 POLYSUBSTITUTED DERIVATIVES OF 2-ARYL-6-PHENYL-IMIDAZO[L,2-A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2012-10-17 EP disclosed
US-8148370-B2 Polysubstituted derivatives of 2-aryl-6-phenyl-imidazo[1,2-a]pyridines, and preparation and therapeutic use thereof SANOFI-AVENTIS (FR) 2012-04-03 US disclosed
US-20110065699-A1 POLYSUBSTITUTED DERIVATIVES OF 2-ARYL-6-PHENYL-IMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065699-A1 POLYSUBSTITUTED DERIVATIVES OF 2-ARYL-6-PHENYL-IMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF ABL1, JAK2, REN NR4A2 1531/4885KCNH2 1429/4885CYP2C9 408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.